Proteostatic regulation of glioblastoma stemness
Proteostatic regulation of glioblastoma stemness
批准号:
MR/X018318/1
负责人:
Florian Siebzehnrubl
金额:
$168.93万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2023
资助国家:
英国
项目状态:
未结题
起止时间:
2023 至 --
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Glioblastoma is the most aggressive type of brain cancer in adults. There is no cure, and most patients die within 15-18 months after diagnosis, even with treatment. Developing effective therapies against glioblastoma is very difficult, because these cancers are made up of a very diverse mixture of different cancer cells. We have found that a type of glioblastoma cells that is more aggressive than other cells from this cancer also contains more proteins than less aggressive glioblastoma cells. We think this allows more aggressive glioblastoma cells to grow quicker which helps these cells to be more aggressive and regrow into new tumours after treatment. Our project will investigate differences in proteins between more aggressive and less aggressive glioblastoma cells to find new ways for treating glioblastoma by stopping more aggressive cells from growing. We want to understand how protein production is conducted in each glioblastoma cell type, and we will combine different ways of investigating proteins inside glioblastoma cells. This will allow us to study not only the type of proteins being made, but also how they interact with one another and how they are broken down. As part of our project, we will investigate the protein HECTD1 since it controls the factory which makes proteins, called the ribosome. We will test whether HECTD1 helps more aggressive glioblastoma cells to make more protein and therefore helps glioblastomas to grow back after therapy. This may help find new ways of treating glioblastoma. Finally, we are using a new type of microscope for measuring protein amounts inside glioblastoma cell types and this is exciting because this technology has the potential to readily identify more aggressive glioblastoma cells, with increased sensitivity and quicker than ever before. We will test this in human patient material to evaluate its diagnostic/prognostic value. This new technology could help other scientists and clinicians in the future by making it easier to identify and study more aggressive cancer cells.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Defining the roles of fibroblast growth factor receptors on glioblastoma stem-like and non-stem cell populations
-
批准号:MR/S007709/1
-
项目类别:Research Grant
-
资助金额:$81.13万
-
财政年份:2019
-
负责人:Florian Siebzehnrubl
-
依托单位:
国内基金
海外基金
登录
查看更多内容
糖尿病ED中成纤维细胞衰老调控内皮细胞线粒体稳态失衡的机制研究
-
批准号:82371634
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:赵福军
-
依托单位:
PRNP调控巨噬细胞M2极化并减弱吞噬功能促进子宫内膜异位症进展的机制研究
-
批准号:82371651
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:赵栋
-
依托单位:
CBP/p300-HADH轴在基础胰岛素分泌调节中的作用和机制研究
-
批准号:82370798
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:王晓
-
依托单位:
精氨酸调控骨髓Tregs稳态在脓毒症骨髓功能障碍中的作用研究
-
批准号:82371770
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:宁铂涛
-
依托单位:
Got2基因对浆细胞样树突状细胞功能的调控及其在系统性红斑狼疮疾病中的作用研究
-
批准号:82371801
-
项目类别:面上项目
-
资助金额:47.00万元
-
批准年份:2023
-
负责人:周海波
-
依托单位:
TIPE2调控巨噬细胞M2极化改善睑板腺功能障碍的作用机制研究
-
批准号:82371028
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:赵慧
-
依托单位:
亚低温调控颅脑创伤急性期神经干细胞Mpc2/Lactate/H3K9lac通路促进神经修复的研究
-
批准号:82371379
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:冯军峰
-
依托单位:
PfAP2-R介导的PfCRT转录调控在恶性疟原虫对喹啉类药物抗性中的作用及机制研究
-
批准号:82372275
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:刘耀宝
-
依托单位:
α-酮戊二酸调控ACMSD介导犬尿氨酸通路代谢重编程在年龄相关性听力损失中的作用及机制研究
-
批准号:82371150
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:侯书乐
-
依托单位:
mPFC-VTA-NAc多巴胺能投射调控丙泊酚麻醉—觉醒的机制研究
-
批准号:82371284
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:许涛
-
依托单位: